DS
ATYR

David Shaw’s aTyr Pharma ATYR Stock Holding History

David Shaw’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-83,312
Closed -$60.1K – 5097
2025
Q3 		$60.1K Buy
83,312
+68,026
+445% +$308K ﹤0.01% 4388
2025
Q2 		$77.5K Buy
+15,286
New +$60.1K ﹤0.01% 4142
2022
Q2 		– Sell
-18,808
Closed -$101K – 5845
2022
Q1 		$101K Buy
+18,808
New +$107K ﹤0.01% 4995
2016
Q1 		– Sell
-1,055
Closed -$145K – 3833
2015
Q4 		$145K Buy
+1,055
New +$150K ﹤0.01% 3626

Other funds holding ATYR

RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

David Shaw's ATYR Position: Q4 2025 in Review

David Shaw sold out of aTyr Pharma (ATYR) in Q4 2025, closing a stake of 83,312 shares — an estimated $60.1K sold.

David Shaw first reported a position in ATYR in Q4 2015 and held it in 4 quarters. The position peaked at $145K in Q4 2015. 84 funds tracked by Wall St. Rank hold ATYR as of Q4 2025.

  • David Shaw reported no remaining aTyr Pharma position as of Q4 2025 after selling out during the quarter.
  • David Shaw sold 83,312 aTyr Pharma shares in Q4 2025, an estimated $60.1K.
  • David Shaw first reported a position in aTyr Pharma in Q4 2015 and held it in 4 quarters.
  • David Shaw's aTyr Pharma position peaked at $145K in Q4 2015.
  • 84 funds tracked by Wall St. Rank held aTyr Pharma as of Q4 2025.

Based on D.E. Shaw & Co's 13F filing for Q4 2025, filed 17 Feb 2026.